Articles
30 September 2025

Frequency of low-density-lipoprotein-cholesterol measurement and risk of major adverse cardiovascular outcomes: a 5-million-person nationwide cohort study

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
13
Views
60
Downloads

Authors

Cardiovascular disease (CVD) is a leading cause of mortality globally and in the UK, with significant efforts focused on early risk identification and prevention. Elevated low-density lipoprotein cholesterol (LDL-C) is a key modifiable risk factor for cardiovascular disease (CVD), yet the impact of LDL-C monitoring frequency on major adverse cardiovascular events (MACE) remains unclear. This study evaluated the relationship between LDL-C measurement frequency and the risk of MACE in a large, nationwide cohort. A retrospective cohort study using anonymised electronic health records from the Clinical Practice Research Datalink (CPRD) Aurum, linked to hospitalisation, social deprivation, and mortality data. The cohort included individuals registered for at least one year with at least one recorded low-density LDL-C measurement between 1 January 2000 and 31 December 2022. The primary outcome was MACE, defined as a composite of non-fatal coronary heart disease, non-fatal stroke, or cardiovascular death. Multivariable Cox proportional hazards models and Kaplan-Meier survival plot were used to estimate the incidence and hazard ratios (HRs) by LDL-C monitoring frequency. The study cohort comprised 5,133,574 individuals, with 2,733,144 (53.2%) being women. The median follow-up duration was 3.31 years (IQR: 7.39-12.11). Among the 5,133,574 individuals, the incidence of MACE declined with more frequent LDL-C monitoring, from 1937.0 (95% CI: 1928.2-1945.8) events per 100,000 person-years (one measurement) to 1615.4 (95% CI: 1605.8-1625.0), 1484.6 (95% CI: 1473.7-1495.6), and 1204.9 (95% CI: 1200.1-1209.6) for those with two, three, and four or more measurements, respectively. Compared to individuals with one LDL-C measurement, the adjusted HRs for MACE were 0.703 (95% CI: 0.698-0.709), for two measurements, 0.570 (95% CI: 0.565-0.575) for three, and 0.312 (95% CI: 0.310-0.314) for four or more. The Kaplan-Meier curve demonstrated improved event-free survival with increased LDL-C monitoring (log-rank p<0.0001). More frequent LDL-C monitoring was associated with a lower risk of MACE. These findings highlight the potential benefits of regular LDL-C monitoring as a potentially impactful strategy for CVD prevention and long-term risk management.

Altmetrics

Downloads

Download data is not yet available.

Citations

1. World Health Organization. Cardiovascular diseases (CVDs). Accessed: May 16, 2025. Available from: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
2. National Institute for Health and Care Excellence. Background information- CVD risk assessment and management. Accessed: May 16, 2025. Available from: https://cks.nice.org.uk/topics/cvd-risk-assessment-management/background-information/burden-of-cvd/
3. World Health Organization. Cardiovascular diseases. Accessed: May 16, 2025. Available from: https://www.who.int/health-topics/cardiovascular-diseases
4. Rong S, Li B, Chen L, et al. Association of low-density lipoprotein cholesterol levels with more than 20-year risk of cardiovascular and all-cause mortality in the general population. J Am Heart Assoc 2022;11:e023690. DOI: https://doi.org/10.1161/JAHA.121.023690
5. Cholesterol Treatment Trialists' (CTT) Collaborators, Mihaylova B, Emberson J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012;380:581-90. DOI: https://doi.org/10.1016/S0140-6736(12)60367-5
6. Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA 2016;316:1289-97. DOI: https://doi.org/10.1001/jama.2016.13985
7. National Institute for Health and Care Excellence. Recommendations | Cardiovascular disease: risk assessment and reduction, including lipid modification. Accessed: May 24, 2025. Available from: https://www.nice.org.uk/guidance/ng238/chapter/Recommendations#initial-lipid-measurement-and-referral-for-specialist-review
8. Grundy SM, Stone NJ, Bailey AL, et al. 2018. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/ APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary. Circulation 2019;139:e1082-143. DOI: https://doi.org/10.1161/CIR.0000000000000624
9. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J 2020;41:111-88. DOI: https://doi.org/10.1093/eurheartj/ehz455
10. Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA 2018;319:1566-79. DOI: https://doi.org/10.1001/jama.2018.2525
11. McCormack T, Dent R, Blagden M. Very low LDL-C levels may safely provide additional clinical cardiovascular benefit: the evidence to date. Int J Clin Pract 2016;70:886-97. DOI: https://doi.org/10.1111/ijcp.12881
12. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372:2387-97. DOI: https://doi.org/10.1056/NEJMoa1410489
13. Forbes CA, Quek RGW, Deshpande S, et al. The relationship between Lp(a) and CVD outcomes: a systematic review. Lipids Health Dis 2016;15:95. DOI: https://doi.org/10.1186/s12944-016-0258-8
14. Bosco E, Hsueh L, McConeghy KW, et al. Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review. BMC Med Res Methodol 2021;21:241. DOI: https://doi.org/10.1186/s12874-021-01440-5
15. Herrett E, Gallagher AM, Bhaskaran K, et al. Data resource profile: clinical practice research datalink (CPRD). Int J Epidemiol 2015;44:827-36. DOI: https://doi.org/10.1093/ije/dyv098
16. Virani SS, Aspry K, Dixon DL, et al. The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint clinical perspective from the National Lipid Association and the American Society for Preventive Cardiology. Am J Prev Cardiol 2023;13:100472. DOI: https://doi.org/10.1016/j.ajpc.2023.100472
17. Benner JS, Tierce JC, Ballantyne CM, et al. Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy. Pharmacoeconomics 2004;2:S13-23. DOI: https://doi.org/10.2165/00019053-200422003-00003
18. Mazhar F, Hjemdahl P, Clase CM, et al. Intensity of and adherence to lipid‐lowering therapy as predictors of major adverse cardiovascular outcomes in patients with coronary heart disease. J Am Heart Assoc Cardiovasc Cerebrovasc Dis 2022;11:e025813. DOI: https://doi.org/10.1161/JAHA.122.025813
19. Navar AM, Wang TY, Li S, et al. Lipid management in contemporary community practice: Results from the Provider Assessment of Lipid Management (PALM) Registry. Am Heart J 2017;193:84-92. DOI: https://doi.org/10.1016/j.ahj.2017.08.005
20. Boekholdt SM, Hovingh GK, Mora S, et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol 2014;64:485-94. DOI: https://doi.org/10.1016/j.jacc.2014.02.615
21. Foley TR, Singh GD, Kokkinidis DG, et al. High-intensity statin therapy is associated with improved survival in patients with peripheral artery disease. J Am Heart Assoc 2017;6:e005699. DOI: https://doi.org/10.1161/JAHA.117.005699
22. Akyea RK, Kai J, Qureshi N, et al. Sub-optimal cholesterol response to initiation of statins and future risk of cardiovascular disease. Heart 2019; 105:975-81. DOI: https://doi.org/10.1136/heartjnl-2018-314253

How to Cite



1.
Ngina DM, Doehner W, Ntaios G, Nartey Y, Akyea RK. Frequency of low-density-lipoprotein-cholesterol measurement and risk of major adverse cardiovascular outcomes: a 5-million-person nationwide cohort study. Global Cardiol [Internet]. 2025 Sep. 30 [cited 2025 Oct. 5];3(3). Available from: https://www.globalcardiology.info/site/article/view/85

Share